



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP	CODE:	
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: https://magellanrx.com/member/external/commercial/common/doc/en-us/phi disclosure authorization.pdf				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP	CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PER	SON:	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY DURATION OF THERAPY (SPE	RENEWAL CIFIC DATES):	IF RENEWAL: DATE TH	ERAPY INITIATED:	

Continued on next page








Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 □ Ankylosing spondylitis □ Moderate to severely active Crohn's dise □ Moderate to severe plaque psoriasis □ Moderate to severe active psoriatic arthr □ Moderate to severely active rheumatoid □ Plaque Psoriasis □ Active non-radiological axial spondylarth □ Other DiagnosisICD-10 Company 	ritis arthritis ritis			
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.				
Has the patient tried and had an inade	.	of Enbrel? 🗆 Yes 🗆 No		
☐ Yes ☐ No (Provide NSAIDs and da	and failure of at least TWO non-steroid	al anti-inflammatory agents (NSAIDs)?		
For moderate to severely active Crohn Does the patient have documented tri methotrexate, azathioprine, and/or 6-	ial and failure on oral immunosuppressi	ve therapy (i.e., corticosteroids,		
Has the patient had at least a 3 month	atic arthritis, also answer the following: a trial and failed previous therapy with a methotrexate,sulfasalazine [Azulfidine],	an oral non-biologic disease modifying		
-	sease such as chronic alcohol abuse/alco or elevated liver enzymes? Yes N			









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
For moderate to severely active rheumatoid arthritis, als	so answer the following:
-	r oral non-biologic disease modifying anti-rheumatic agent
(DMARD) such as Imuran, Ridaura, Arava, Plaquenil, or s	
Does the patient have chronic liver disease such as chronic liver	nic hepatitis, fatty liver, nonalcoholic steatohepatitis
(NASH), or elevated liver enzymes)? ☐ Yes ☐ No	
Has the patient been treated with and had an inadequat	e response to Remicade and/or Orencia? Yes No
Moderate to severe plaque Psoriasis:	
Is the patient ≥18 years of age? □ Yes □ No	
Does the patient have plaques covering > 3% of their bo	dy surface area (RSA) or < 3% of RSA? □ Ves □ No
bots the patient have plaques covering > 370 of their both	
Is topical therapy no longer tolerated or effective with a	gents such as corticosteroids, anthralin, calcipotriene, or
Tazarotene for thepatient? ☐ Yes ☐ No	
Select if the patient has had previous treatment failure v	with the following
□ Phototherapy	
□ Psoralens with UVA light (PUVA)	
□ UVB with coal tar	
Has the patient had previous treatment failure with an o	oral systemic therapy (e.g. acitretin, methotrevate or
cyclosporine)? Yes No	nai systemic incrapy (e.g., activetii), method exace of
If "no" to the above question, does the patient have	a contraindication to ALL oral systemic treatments?*
□ Yes □ No	
*Documentation of a contraindication to ALL oral system	nic treatments must be submitted.
For Active non-radiological axial spondylarthritis:	ve ver vediclerical evial area dulcouthuitie. AND e
Please submit chart notes corroborating patient has acti submitted radiology report documenting the absence of	
Has patient had active axial spondyloarthritis for at least	t 12 months? ☐ Yes ☐ No
Does patient have objective signs of inflammation indicated of normal? Yes No Please submit lab report.	ated by C-reactive protein(CRP) levels above the upper limit
Does patient have documented sacroiliitis on magnetic r MRI report.	esonance imaging (MRI) ? Yes No Please submit

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 08/22/2018 CAT0053 9.15.19







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Does patient have an intolerance to or an inadequate resp	oonse to at least two NSAIDs?
Does patient have fibromyalgia? ☐ Yes ☐ No	
Reauthorization:	
If this is a reauthorization request, answer the following q	uestions:
Is the patient continuing to have a positive clinical responsuse?* ☐ Yes ☐ No	se and remission of disease is maintained with continued
*Must be confirmed by provided chart notes.	
Select if Cimzia is prescribed by one of the following specia	alist:
□ Dermatologist	
☐ Gastroenterologist	
□ Rheumatologist	
Are there any other comments, diagnoses, symptoms, me physician feels is important to this review?	dications tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are covered on all plan information is received.	s. This request may be denied unless all required
ATTESTATION: I attest the information provided is true and the Health Plan, insurer, Medical Group or its designees mainformation necessary to verify the accuracy of the information	y perform a routine audit and request the medical
Prescriber Signature or Electronic I.D. Verification:	Date:
CONFIDENTIALITY NOTICE: The documents accompanying this transmiss	
you are not the intended recipient, you are hereby notified that any disc	losure, copying, distribution, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.